Genetic Diversity and the Human Immunodeficiency Virus Type-1: Implications and Impact by Orville Heslop
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Genetic Diversity and the Human 
Immunodeficiency Virus Type-1: 
 Implications and Impact 
Orville Heslop 




Genetic diversity is the tendency of individual genetic characteristics in a population to vary 
from one another or the potential of a genotype to change or deviate when exposed to 
environmental or genetic factors (Dale & Park, 2010). The extent to which the trait or the 
genotype tends to vary describes genetic variability and at the molecular level variability is 
measured by determining the rate of mutation. Genetic diversity however measures the 
number of the actual variation of species in a population (Dale & Park, 2010).  
The scope of references to the numerous microbes which demonstrate both genetic diversity 
and variability within their genomes are beyond the limits of this chapter. Our focus is 
therefore confined generally to those species which would best explain the nature, mode 
and factors which influence mutational changes which can be measured.  
1.2 Factors influencing diversity 
The genetic response of micro-organisms to host and various environmental selective 
pressures may vary differentially among species. The outcome characterized by the 
influence of these factors often result in minor or major mutational changes and host 
adaptability. 
Organisms of one genotype such as mumps, rubella and the measles virus do not 
demonstrate the type variability or diversity as the influenza, human immunodeficiency 
virus (HIV) and hepatitis viruses. Consequently the predictability of the epidemiology of 
highly genetically diversified agents is often more challenging. The etiology of an influenza 
outbreak is invariably the result of genetic re-assortment of different influenza strains. 
Metzulan et al., (2004) report that genetically distinct multiple viruses can combine to cause 
an influenza B epidemic in a community and that the frequent re-assortment among these 
viruses play a role in generating the genetic diversity of influenza B viruses (Metzulan et al., 
(2004). There are several factors which influence diversity and are dependent on the species 
involved, the host with various immunological selective pressures, environmental pressures 
as well as treatment intervention resulting in development of resistance genes to 
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antibacterial, antiviral, antifungal and antiprotozoal agents. Resistance to several 
antimicrobials used as therapeutic agents relative to the various and specific categories of 
microorganisms have been well documented (Murray et al., (2007). The human 
immunodeficiency virus is demonstrably the most genetically diverse microorganism and is 
an important reference point in understanding and appreciating the impact of genetic 
diversity. Whatever the resulting impact of mutational changes, it is important to determine 
how these changes impact the definitive host, their influence on transmission of the 
infecting agent and whether these changes are measurable and can be used as an 
epidemiological tool in clinical and laboratory diagnosis.  
1.3 Measuring genetic diversity 
The etiological agent in an outbreak can be determined based on phenotypic characteristics 
which are the observable properties of the organism measured under controlled laboratory 
settings. Genetic characteristics are, however, more difficult to measure employing various 
molecular methods and highly trained individuals. The major difference between 
phenotypic (physiological) and genetic characteristics, is observed in altered physiological 
changes as opposed to properties of micro-organisms which are genetically inherited. The 
importance of genotyping as an epidemiological tool in determining mutant genes in drug 
resistance cannot be overemphasized. This involves the genome of micro-organisms and is 
the focal point for single or multiple mutational changes. 
Behavioural changes of micro-organisms are the results of mutational changes in genes and 
consequently are responsible for the various features exhibited by these organisms. Included 
in the changing behavioral patterns of microorganisms and in particular bacteria, may range 
from differences in biochemical reactions, growth requirements, tolerance to various 
temperatures and resistance to therapeutic agents. These changes may be demonstrated 
under controlled laboratory conditions by assays and specific methods designed to 
determine phenotypic and genotypic characteristics.  
2. Background of the problem 
The first cases of acquired immunodeficiency syndrome (AIDS) were recognized in the USA 
during 1981 (Morbidity Mortality Weekly., 1981). By 1983 the human immunodeficiency 
virus - type 1 (HIV-1) had been identified and was later confirmed to be the aetiologic agent 
of AIDS (Barré-Sinoussi et al., 1983). At the end of 2000 an estimated 60 million cases of 
human immunodeficiency virus –type 1 (HIV-1) infection were reported globally (Barré-
Sinoussi, 1983; Piot, 2001). The extensive genetic variation which characterizes HIV-1 is an 
important feature of the HIV/AIDS epidemic (Robertson et al., 2000). The genetic variability 
of HIV-1 is generated by the lack of proof reading ability of the reverse transcriptase, the 
rapid turn-over of HIV-1 in vivo, host selective immune pressures and recombination events 
during viral replication (Heyndrickx, 2000; Ho, 1995; Leitner, 2005; Michael, 1995; Tatt, 
2001). This has several public health implications although the biological significance is not 
known (Loussert-Ajaka, 1998; Tatt, 2001). The HIV-1 subtypes vary in the geographical 
distribution of the virus (Heyndrickx, 2000; Tatt, 2001). The differences in HIV-1 subtypes 
and geographic diversity impact the development of efficacious vaccines, diagnostic testing 
and antiviral therapy (Borrow, 1997; Loussert-Ajaka, 1998; Piot, 2001). On the other hand, 
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the genetic hetero-geneity in HIV may aid the surveillance of transmission patterns within 
the epidemic (Robertson et al., 2000).  
The World Health Organization reports that the economies of Caribbean countries, which 
rely heavily on tourism components are substantially affected by the HIV epidemic 
(UNAIDS/ WHO, 2004). In addition, most countries in the Caribbean are limited in their 
capacity to control and track the evolution of the epidemic. It is therefore necessary to 
strategize surveillance programmes which include the determination of existing HIV-1 
subtypes to understand the changing nature of the epidemic and measures to control spread 
of the virus in the Caribbean (d'Cruz-Grote, 1996; Delwart, 1995).  
In Jamaica, the first case of AIDS was reported in 1983 and the number of reported cases 
increased to over 12,000 by 2007 (Ministry of Health, Jamaica, 2007). Being a tourist 
destination increases Jamaica’s potential for introduction of different HIV-1 subtypes and 
circulating recombinant forms (CRFs) of the virus into the Jamaican population. The aim of 
this study is to determine the HIV-1 subtypes in HIV-1 infected persons and the molecular 
epidemiology of the virus in Jamaica. The main objectives are to: 
i. determine current subtypes and recombinant forms of HIV-1  
ii. investigate the relationships between HIV-1 subtype strains in terms of transmission 
and disease  progression in Jamaica 
iii. evaluate the heteroduplex mobility assay (HMA) as a sub typing method in the 
HIV/AIDS epidemic in  Jamaica 
3. Literature review 
3.1 Human Immunodeficiency Virus - type 1 (HIV-1) 
Human immunodeficiency virus - type 1 (HIV-1), a member of the genus Lentivirinae, and 
family Retroviridae is closely related to its primate retrovirus HIV-2 and is the cause of 
acquired immunodeficiency syndrome (AIDS) (Chiu, 1985; Peeters, 2000). While HIV-1 is 
responsible for the vast majority of cases in the AIDS pandemic, HIV-2 is almost exclusively 
confined to Africa and, to a large extent, is responsible for the epidemics seen in that region 
(Peeters, 2000).  
HIV-1 is divided into three genetic groups: group M (major or main), group O (outlier) and 
N (new or non-M, non-O) group M being responsible for the AIDS pandemic accounting for 
over 90% of HIV infections worldwide (Hemelaar et al., 2006). Nine pure subtypes of HIV-1 
group M are currently known (A-D, F- H, J and K). These subtypes are further into sub-
subtypes such as F (F1 and F2 and A (A1, A2 and A3). Subtypes and sub-subtypes may form 
additional mosaic forms when individuals are dually or multiply- infected by different 
strains of HIV-1 giving rise to known recombinant forms (Burke, 1997) - CRFs, - drug 
resistance differences). To date, over 40 CRFs are recognized (Taylor et al., 2008).  
3.2 Morphology and genomic organization of human immunodeficiency virus -type 1 
(HIV-1) 
Structure of HIV-1 A schematic presentation of the structure of the human 
immunodeficiency virus - type 1 (HIV-1) as described by Hahn, (1994 - 42) is shown in 
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Figure 1. Like the other human retroviruses the mature virion of HIV comprises icosahedral 
cores containing the RNA genome, the RT enzyme and gag proteins surrounded by an 
envelope which is acquired as the virion buds through the host cell membrane (Folks & 
Khabbaz, 1998). Morphologically HIV-1 differs from HTLV-1 with respect to the nucleoid, 
the dense inner part of the core, and the pronounced glycoprotein spikes of the envelope. 
However the overall diameter of the mature particles of both viruses is 100-120 nm in 
diameter (Folks, 1998; Hahn, 1994). The viral core contains the viral genome, which 
comprise two identical copies of single stranded positive sense RNA, each of which encodes 
the complete structural, enzymatic and regulatory proteins (Hahn, 1994).  
 
Fig. 1. Human immunodeficiency virus - type 1 (HIV-1) Adapted: Hahn et al (Hahn, 1994) 
The structural proteins that form the nucleocapsid and matrix shell are induced by the gag 
gene. The nonstructural gene products of the HIV-1 pol gene region include the reverse 
transcriptase (RT), integrase and protease (Folks, 1994; Guatelli, 2002; Hahn, 1994). The lipid 
envelope encoded by the env gene contains structural proteins with a surface domain (SU, 
gp120) and transmembrane domain (TM, gp41) presented as trimeric spikes on the surface 
of the virion (Folks, 1994; Guatelli, 2002; Hahn, 1994; Kwong, 1998). The viral envelope 
contains conserved (C) and variable (V) regions, is poorly immunogenic, and contains 
binding sites for CD4 T cells on gp120 and chemokine co-receptors (Kwong, 1998; Wyatt, 
1998a; 1998b). These, so-called, co-receptors are masked by variable loops V2 and V3 of 
gp120 until the CD4 molecule is engaged (Rizzuto, 1998).  
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3.3 Genome organization of HIV-1 
The complete sequence of HIV-1 contains a 9.2 kb genome (Folks, 1994). The genomic map 
of the HIV-1 viral genome is well documented and is shown in Figure 2. (Hahn, 1994). In 
keeping with the general structure of primate lentiviruses, the HIV-1 genome comprises 9 
genes, including 3 structural, gag, polymerase (pol), envelope (env), and 6 nonstructural, tat, 
rev, vip, nef, vpu and vpr genes which are flanked by long terminal repeat (LTR) sequences. 
The HIV-1 LTR is approximately 640 bp long and is segmented into the U3, R, and U5 
regions. The genes of HIV-1, corresponding proteins and functions have been reviewed, as 
shown in Table 1. Guatelli et al (2002). 
 
Fig. 2. Genome arrangement/map of the HIV-1 genome  - adapted: Hahn et al (1994) 
3.4 HIV-1 diversity and molecular epidemiology 
3.4.1 HIV-1 diversity 
The genetic diversity of HIV-1 has resulted in differences among the subtypes in the LTR 
sequences, transcriptional promoters, accessory and regulatory genes such as nef, tat, rev and 
vpu (Geretti, 2002). The basis of genetic diversity of HIV-1 subtypes is, to a large extent, the 
consequence of a high mismatch error rate in the reverse transcriptase (RT). In addition, 
there is an absence of exonuclease proof reading activity (Spira et al., 2003). Other factors 
which contribute to genetic diversity include the replicative rate of each viral subtype, 
mutational changes arising in each replicative cycle, genomic recombination and viral 
fitness (Robertson, 1995; Spira, 2003). Evolutionary changes in the genome may result from 
host, environmental and other selective pressures (Hu, 2005; Piot, 2002; Quinones-Mateu, 
1999; Renjifo, 2002).  
In comparison to the env gene the pol and the gag regions are much more intolerant to 
mutation primarily because they encode core protein sequences which are relatively 
inflexible. Genetic changes in pol and gag may give rise to drug resistance as some 
antiretroviral drugs are directed against the RT and protease proteins encoded by these 
genes (Spira et al., 2003). For example, 6.8%–10% variation has been shown in the RT of 
clade B isolates from Ethiopia whereas, intra-clade differences of 3.5–5% have been reported 
in isolates from Africa, India and South America (Loemba, 2002; Loemba, 2002a; 2002b). 
Differences in the degree of variation among subtypes also have been observed in LTR 
sequences and in the transcriptional promoters involved in HIV replication (Montano, 1997). 
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Other variations observed among HIV-1 subtypes include 14.4%–23.8% differences in the 
sequences of viral regulatory protein, nef (Jubier-Maurin et al., 1999). Subtype C contains a 
unique rev protein and an enlarged vpu product while subtype D expresses a tat protein 
with a C-terminus deletion (Gao & Robertson, 1998 ). Also a significantly shorter envelope 
V1-V2 loop sequences and fewer potential N-linked glycosylation sites have been shown in 
subtypes C and A compared to subtype B (Chohan et al., 2005).  
Differences in co-receptor usage and syncytia inducing capacity between subtypes have also 
been reported (Cocchi, 1995; Deng, 1996; Fenyö, 1998; Tersmette, 1988; Worgall, 1999). For 
example some subtypes may exhibit enhanced susceptibility to CCR5 (R5) inhibition 
(Marozsan et al., 2005). Subtype B viruses for example appear as R5 viruses in early infection 
and emerge as X4 viruses in advanced disease while recombinant subtype BG strains appear 
to be X4 viruses regardless of the clinical stage of disease (Pérez-Alvarez et al., 2006). In 
contrast subtypes A and C appear infrequently as X4 viruses, even in advanced disease. 
Subtype C viruses however, are able to switch from CCR5 to CXCR4 using mechanisms 
similar to those used by subtype B viruses (Pollakis et al., 2004).  
Variations among HIV-1 strains also have been seen in the ability to infect Langerhans cells. 
This tropism has been linked to vaginal/cervical transmission of the virus (Dittmar, 1997; 
Hu, 1999).  
Subtype diversity in response to antiretroviral drugs has been reported (Loemba  2002a, 2002b; 
Miller, 2007; Quinones-Matue, 1998; Velazquez-Campoy, 2002). Changes in nucleotide 
sequences play an important role in conferring resistance to each antiretroviral drug or even 
entire classes of nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTI and 
NNRTI) and protease inhibitors (PI) (Velazquez-Campoy, 2002; Quinones-Matue, 1998; 
Tantillo, 1994). While the majority of the reports on resistance to antiretroviral drugs and 
subtype diversity have focused on subtype B it has been noted that Y181C and Y1811 
mutations, respectively can render HIV-1 group O and all HIV-2 strains resistant to the entire 
NNRTI class of drugs (Leitner, 2005; McCutchan, 2004; Papuashvili, 2005;Tantillo, 1994). 
3.4.2 Global distribution of HIV-1 subtypes, sub-subtypes, circulating recombinant 
forms (CRFs), and unique recombinant forms (URFs) 
Majority of the subtypes, subtypes and several CRFs are found in Africa (Geretti, 2002; 
Leitner, 2005; McCutchan, 2004; Yang, 2005). The phylogenetic classification of HIV-1 
subtypes including sub-subtypes, CRFs and URFs are well documented (Tables 1.) (Taylor, 
2008)  The profile of HIV-1 subtypes fluctuates in some countries. For example, in 1996 the 
dominant subtypes in Eastern Europe were subtypes B in homosexuals, C in heterosexuals 
and G in nosocomially infected patients but by 2003 subtype A1 accounted for more than 
90% of infections (Papuashvili et al., 2005). In Western Europe subtype B initially dominated 
the epidemic but the prevalence of non-subtype B has been noted to be steadily increasing 
(deMendoza, 2005; Monno, 2005; Taylor, 2005). Non-B subtypes were also noted to be 
increasing in Canada (Akouamba et al., 2005). Emerging recombinant forms are presently 
seen in several regions including sub-subtypes B/CRF_O1AE, A/CRFO2_AG and 
A/CRFO6-cpx seen in South East Asia, Uzbekistan and Estonia, respectively (Carr, 2005; 
Tovanabutra, 2004; Zetterberg, 2004;). A new CRF designated CRF18_cpx was recently 
isolated in Cuba (Thomson et al., 2005). With the exception of Cuba and Jamaica, Caribbean 
islands have reported subtype B as virtually the only subtype present in the other regions of 
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the Caribbean (Cleghorn, 2000; Gittens, 2003, Heslop, 2009; Thomson, 2005; Vaughan, 2003). 
Five non-B subtypes including A, C, D, E and J have been reported in Jamaica (Heslop et al., 
2009). It is important to note that the predominant subtype B in the United States and other 
countries is associated with a homosexual epidemic, while its association with a 
heterosexual epidemic has been reported only in the Caribbean (Avila et al., 2002).  
 
Adapted from Taylor et al (2008). 
Table 1. Phylogenetic Classification and global distribution of HIV-1 
3.5 Molecular detection of HIV-1 infection and determination of diversification among 
the virus subtypes 
3.5.1 Molecular detection of HIV-1 infection 
The HIV-1 DNA polymerase chain reaction (PCR) assay which detects HIV proviral DNA in 
PBMC and HIV-1 reverse transcriptase polymerase chain reaction (RT-PCR) assay for 
detection of HIV-1 RNA virions in plasma are highly sensitive and independent of the host 
responses (Diagnostic Tests, 1998; Eisenstein, 1990). The nucleic acid amplification methods 
involve exponential amplification of viral nucleic acid sequences allowing detection of low 
numbers of HIV infected lymphocytes in patients (Schochetman, 1989).  
The PCR assays enable the resolution of early HIV infection before seroconversion and have 
been particularly useful in the early identification of HIV infected infants born to HIV 
seropositive women where antibody tests may be ineffective due to passive transfer of 
maternal antibodies (Sheppard, 1993). 
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3.5.2 Human Immunodeficiency Virus -type 1 subtype determination 
Several techniques for HIV-1 subtype determination have been described (Myers, 1995; Ou 
Cy, 1992). These comprise molecular based methods including genetic sequencing, probe 
hybridization assay, restriction length polymorphism (RFLP) analysis, subtype-specific PCR, 
combinatorial melting assay, heteroduplex mobility assay (HMA) and a phenotypic method 
of serotyping (Cornelissen, 2007; Delwart, 1995; Luo,1998; Murphy, 1999; Peeters, 1998; 
Robbins, 1995; van Harmelen, 1999). Of these methods HMA has been shown to be reliable, 
rapid and inexpensive (Delwart, 1995; Loussert-Ajaka, 1998; van der Auwera, 2000). 
Currently the two most widely used methods for HIV-1 subtype determination are genetic 
sequencing and phylogenetic analysis and HMA. Molecular analysis has been used 
extensively in the HIV/AIDS pandemic to determine transmission patterns of HIV-1 
(Leitner et al, 1999). Recently routine HIV-1 genotyping has been proposed as a tool to 
identify dual HIV-1 infections (Cornelissen et al, 2007). 
3.5.3 DNA sequencing and phylogenetic analysis 
Sequencing and phylogenetic analysis are still the most accurate approach for characterizing 
viral genomes in identifying new subtypes, sub-subtypes, recombinant, complex and unique 
forms of HIV-1 and are well documented (Leitner, 2005; Loussert-Ajaka, 1998; Tatt, 2001). 
These methodologies have been important tools in determining sequence relatedness, 
mutational changes relating to viral ancestry, the relative time of viral introduction, 
mutations associated with antiretroviral drug resistance, viral transmission patterns and 
other epidemiological information (Leitner et al., 1998). The definitive method of subtyping 
HIV-1 is the genetic sequencing of the envelope (env), group antigen (gag) or polymerase 
(pol) The main advantages of this method are that it allows the determination by 
phylogenetic analysis of the relatedness among HIV sequences, the study of the evolution of 
HIV quasispecies in different hosts linked to a common source of infection, and the study of 
virus transmission patterns among different risk groups (Diaz, 1997; Holmes, 1995; Leitner, 
1999). However genetic sequencing is expensive, time consuming and requires highly 
qualified personnel (Hu, 2005; Leitner, 2005; Loussert-Ajaka, 1998; Tatt, 2001). In addition 
phylogenetic methods have been widely used to investigate alleged person to person 
transmission of the virus, for example, from health care professionals to their patients 
(Holmes, 1993; Ou, 1992). These molecular techniques have been useful in confirming 
transmissions in household settings, in forensic investigations including sexual offences, 
and cases of intentional HIV infection (Albert, 1994; APRI newsletter, 2001; Morb Mortal 
Wkly Report, 1994). 
3.5.4 Heteroduplex mobility assay (HMA) 
The heteroduplex mobility assay (HMA) has been shown to be a reliable and standardizable 
method of HIV-1 subtyping (Holmes, 1995; Ou, 1992). Its usefulness as a tool to study HIV 
diversity in different populations has been demonstrated (APRI Newsletter, 2001; Holmes, 
1993; Hu, 2005). The HMA may be used to distinguish strains of HIV-1 and to trace viral 
quasispecies within individuals and within populations (Albert, 1994; Hu, 2005). It is cost 
effective and correlates well with genetic sequencing and characterization by phylogenetic 
analysis (Delwart, 1993; Heyndrickx, 1998). The HMA has been introduced by UNAIDS in 
several developing countries as a tool for monitoring subtype distribution. The combination 
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of results from HMA gag and env genes allows the detection of intersubtype recombinant 
strains. This is not possible when only one genomic region is typed (Heyndrickx, 2000; 
Loussert-Ajaka, 1998; Tatt, 2001).  
The hypervariable V3 region of env is most frequently used for genetic subtyping by the 
HMA. This is done particularly when there is a need to investigate epidemiologically linked 
infections (Mulder-Kampinga, 1993; Scarlatti, 1993; Weiser, 1993). Other hypervariable 
regions of env such as V1/V2 and V4/V5 are used less in the HMA to trace epidemiological 
linkage (Lamers, 1993; Simmonds, 1990). As opposed to the variable region of V3, subtyping 
of the more conserved tat gene region by HMA was particularly successful in identifying 
epidemiological relationships in cases of person to person transmission of HIV-1 (Simmonds 
et al., 1990).  
4. Molecular characterization and epidemiology of Human Immunodeficiency 
Deficiency Virus - type 1 (HIV-1) in Jamaica 
4.1 Introduction   
This chapter describes the study which was undertaken to determine the HIV-1 subtypes in 
Jamaica and assess the heteroduplex mobility assay (HMA) as a method for tracking the 
HIV-1 epidemic. The HMA was introduced by the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) in several developing countries as a tool for monitoring HIV-1 
subtype distribution (Heyndrickx, 2000; Loussert-Ajaka, 1998). An abbreviated account of 
the clinical, immunological and laboratory characteristics of a representative sample of the 
cohort of HIV-1 infected patients which was studied is also presented. In this chapter the 
terms HIV-1 isolates and HIV-1 proviral DNA are used inter- changeably. 
4.2 Materials and methods 
4.2.1 Study population 
The study population included EDTA blood samples collected from 1341 consecutive HIV-1 
infected patients presenting at designated health care centres situated in several parishes 
throughout Jamaica were received by the Microbiology Department, University Hospital of 
the West Indies (UHWI), a tertiary care centre, for leucocyte immunophenotyping. Jamaica 
has 14 parishes from which samples were obtained from 12 parishes. Hanover and 
Trelawny were the only parishes that were not included. A data abstraction form was used 
to collect socio-demographic and clinical information from the hospital records of 94 
patients who were seen at UHWI. The medical records of the patients seen at other 
healthcare facilities were not available for the study. 
The peripheral blood mononuclear cells (PBMC) were separated from remnant EDTA blood 
samples of each patient using density gradient centrifugation with Histopaque® 1077 
(Sigma–Aldrich Inc., St. Louis, Mo, USA) and the cells were kept frozen at – 200C until 
required.  
4.2.2 Immunophenotyping and T lymphocyte enumeration 
Absolute CD3, CD4 and CD8 T lymphocyte counts were determined on EDTA blood 
samples by flowcytometry using the FACSCOUNT system and reagents (Biosciences 
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Immunocytometry Systems, San Jose, CA). The manufacturers’ instructions were followed. 
The established reference ranges for T lymphocyte subsets in the Jamaican adult and 
paediatric populations (unpublished data) were used to evaluate the immune status of the 
patients. At least 1 EDTA blood sample from a healthy blood donor was included, as a 
control, with each test run.  
4.2.3 Polymerase Chain Reaction (PCR) amplification of HIV-1 and gag genes 
Polymerase chain reaction (PCR) was performed on PBMC from 318 patients. Two 
microlitre aliquots of PBMC was used as the DNA template for two-step nested polymerase 
chain reactions (PCR) carried out in a Perkin Elmer 9600 Thermal Cycler (Perkin-Elmer 
Corp. Norwalk, Conn.) using the PCR mixtures and amplification programs described in the 
HIV-1 env/gag HMA subtyping kit manuals, with modifications (Delwart version 5; Heslop, 
2005; van der Auwera, 2000). The HIV-1 HMA subtyping kits which include plasmid clones 
of the complete genome of HIV-1 subtypes A–J of the major M group of HIV-1 sequences 
and primer pairs for PCR amplification of the HIV-1 env and gag genes were obtained from 
the National Institutes of Health (NIH) AIDS Research and Reference Program (Heslop, 
2005; van der Auwera, 2000). The PCR core reagents used were commercially prepared 
(Invitrogen, Life Technologies, Grand Island, NY). 
Due to the high rate of failed amplifications with primers supplied in the HMA kit, the gag 
gene primer pairs were replaced with DT1/DT7 and DT3/DT6 as first and second round 
primers (Delwart, 1995; Tatt, 2000; van der Auwera, 2000). The plasmids containing cloned 
env and gag genes, respectively, were amplified using second round env and gag primers. A 
negative control in which the DNA template was replaced by reagent grade water was 
included with each PCR assay.  
The second round PCR amplification of the env gene using the ED5/ ED12 primers yielded a 
1.2 Kb fragment spanning the V1-V5 coding region of HIV-1 gp120, while the ES7/ES8 
primer pair yielded a 666 bp fragment spanning the V3-V5 coding region of gp120. Second 
round amplification of the gag gene resulted in a 748 bp fragment of the HIV-1 p17/ p 24 
gene.  
The PCR products were resolved by agarose gel electrophoresis carried out in 1.5% agarose 
gel containing ethidium bromide (0.5 µg/ml) at 80 volts for 45 minutes and visualized by 
ultraviolet (UV) illumination. The appropriate kilobase markers and controls were included 
in each run. 
4.2.4 Genotyping of HIV-1 env and gag genes by Heteroduplex Mobility Assay (HMA)  
The heteroduplex mobility assays (HMA) were performed on HIV-1 isolates from 180 
patients. The HMA was performed as previously described with modifications (Loussert-
Ajaka, 1998).  
Both the gag-HMA and env-HMA were performed on each HIV-1 isolate. The subtype 
reference strains were selected following a pilot run of the HMA on 28 samples. Eleven env 
and 12 gag reference subtypes were selected from a panel of reference subtypes to  include 
subtypes A, B, C, D, E, F, G , H and J in the HMA procedure. All subtype B reference strains 
(4 from the gag and 3 from the env) included in the kit were used in the HMA due to the 
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dominance of this clade in the Caribbean and North America. In this method equal volumes 
of the patient HIV strain DNA and reference strain DNA are mixed under certain conditions 
to form heteroduplexes. This is followed by polyacrylamide gel electrophoresis. The HIV 
subtype is identified by the heteroduplex with the highest electrophoretic mobility which is 
the most closely matched heteroduplex formed from the most closely related strains. For the 
formation of heteroduplexes 5µl aliquots of a mixture containing equal volumes (5µl each 
and 1µl annealing fluid) of the second round PCR products of the HIV-1 isolates and the 
reference subtype strains were separated by  polyacrylamide gel electrophoresis using 
CriterionTM precast gels which contained 5% polyacrylamide and 6M urea (Bio-Rad 
Laboratories, Hercules, CA). The heteroduplexes were visualized under UV light after 
ethidium bromide (0.5µg/ml) staining. The HIV-1 subtype assigned was that of the 
heteroduplex with the highest electrophoretic mobility.  
4.2.5 Genotyping of HIV-1 env and gag genes by DNA sequencing and phylogenetic 
analysis 
A total 63 HIV-1 isolates including 5 which were untypable by HMA were subjected to DNA 
sequencing and phylogenetic analysis of the purified PCR product or cloned PCR product. 
The sequencing primers for direct DNA sequencing were the second round PCR primers of 
the gag and env gene regions, respectively as described above.  
4.2.6 Purification and cloning of amplicons of HIV-1 env and gag genes    
The PCR products of the gag and env genes were purified using a commercially prepared kit 
(QIAGEN Inc. Valencia, CA) and cloned using the pGEM-T Easy Vector System Kit 
(Promega Corporation, Madison, WI). The manufacturers’ instructions were followed. 
4.2.7 Confirmation of env and gag clones by Polymerase Chain Reaction (PCR) 
The recombinant clones were subjected to env-DNA PCR and gag-DNA PCR, respectively 
followed by agar gel   electrophoresis to confirm the presence of the cloned DNA inserts, as 
described above. 
4.2.8 Purification of HIV-1 env and gag gene clones 
The plasmid vectors carrying the HIV-1 env and gag gene clones were purified using the 
PlasmidPURETM DNA Miniprep kit (Sigma, St Louis, MO). The procedure followed was in 
accordance with the manufacturer’s instructions. The final product of this procedure was 
highly purified plasmid DNA. The yield of cloned DNA was estimated by agar gel 
electrophoresis of 1-5 µl of the DNA using 1.5% agarose gel and read against an appropriate 
kilobase marker with ethidium bromide staining as described above. The env and gag gene 
clones were stored at -200C until required. 
4.2.9 Cycle sequencing of HIV-1 env, gag amplicons and clones 
Commercially prepared reagents (BigDye® Terminator v3.1 Cycle Sequencing Kit, Applied 
Biosystems) were used for sequencing following the manufacturer’s instructions. Briefly, 
sequence reactions were performed on the different HIV-1 DNA templates, including 
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purified PCR products, purified cloned inserts, double stranded control DNA (pGEM® 
3Zf(+), 0.2µg/µl or 200ng/µl) and negative control DNA templates supplied with the kit. 
Sequence reactions were carried out in a Perkins Elmer 9600 thermocycler using the 
following parameters: 
      960C for 10 seconds 
      500C for 5 seconds    25 cycles 
      600C for 4 minutes 
Following purification of the sequence reactions using the DyeX 2 (QIAGEN, Valencia, CA) 
DNA sequencing was performed using the ABI 3100 analyser (Applied Biosystems, Foster 
City, CA).  
4.2.10 Sequence editing and phylogenetic analysis of HIV-1 env and gag sequences 
Following the cycle sequencing procedure single strand sequences generated  by forward and 
reverse sequencing primers were assembled into contiqs (a contiguous alignment of 
overlapping sequences) using the SequencherTM 4.0 software program (Gene Codes 
Corporation, Ann Arbor, MI). The formed contiqs were edited for ambiguous base pairs 
introduced during sequencing. The chromatograms generated were subsequently compared 
for relationships between the HIV-1 isolates and GenBank reference strains. All sequences 
were imported in the FASTA format for alignment by the ClustalX software programme 
(http://inn-prot.weizmann.ac.il/software/ClustalX.html) (Thompson et al., 1997). 
Alignments were carried out firstly by pairwise matching of the sequences of interest, 
followed by multiple alignments with referenced HIV-1 sequences from GenBank (http://hiv-
web.lanl.gov/ALIGN_CURRENT/ALIGN-INDEX.html). The multiple aligned sequences 
were edited prior to the construction of phylogenetic trees. The PAUP 4.0 software programme 
(Beta version 8 for Windows 95/98/ME/NT/2000/XP, Sinauer Associates, Inc, Sunderland, 
MA) was used to construct rooted and unrooted neighbour-joining phylogenetic trees using 
the SIVCPZ sequence (simian derived virus) of CPZ.GA.CPZGAB (GenBank accession number 
X52154, htpp://hiv-web.lanl.gov/ALIGN_CURRENT/ALIGN-INDEX.html) as the out-group 
(Swofford, 2003). The phylogenetic trees were subsequently bootstrapped (using 1000 
replications) to establish confidence and statistical reliability (Hall, 2001).  
4.2.11 Statistical analyses 
Univariate and multivariate analyses of the patients’ sociodemographic, clinical and 
laboratory data were performed using the Statistical Packages for Social Sciences (SPSS) 
Version 8 software.  
4.3 Results  
4.3.1 Demographic, clinical and immunological characteristics of HIV-1 infected 
patients  
As shown in Table 2, the study population was predominantly heterosexual (90/94, 96%) 
with a preponderance of females (68/94, 72%) and did not contain any injecting drug users 
(0/94, 0%) while the only non-injecting drug used was marijuana (1/94, 1%). Other risk 
factors for HIV infection included inconsistent condom use (21/94, 20%), history of 
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ulcerative (12/94, 13%) and non-ulcerative (15/94, 16%) STI. The percentages of 
antiretroviral drug therapy naïve and antiretroviral drug treated patients were 56% (53/94) 
and 44% (41/94), respectively. The clinical manifestations in the HIV-infected persons are 
summarized in Table 3 and a variety was seen. Constitutional symptoms including weight 
loss occurred in more than three quarters of the patient population and skin rashes in almost 
a half while opportunistic and respiratory infections were present in over one third. Other 
STI were common, over 20% and weight loss was found in just under 20%. There was 1 case 
of Kaposi’s sarcoma while 13% of the population were asymptomatic.  
The CD4 T cell counts were available for 73 patients. No trend was noted in the CD4 T cell 
counts by age and duration of diagnosis of HIV-1 infection for the cohort. However, when 
the patient population was separated into antiretroviral therapy naïve and treated 
categories, CD4 counts were statistically significantly higher in untreated patients (p<0.005, 
Table 4). A significant decreasing trend in CD4 counts with age in untreated patients 
(p<0.05) was observed (Table 5). In contrast no significant correlation was observed with age 
and CD4 counts in antiretroviral drug treated patients (Table 14). In multivariate analyses 
both increasing age in antiretroviral therapy naïve patients and absence of antiretroviral 
drug therapy were identified as independent risk factors for low CD4 counts (p= 0. 022; 95% 
confidence interval (CI), 1.014, 1.197 and p=0.003; 95% CI, 2.096, 35.982, respectively). 
 
Characteristics 94 
Mean age (years) ± SD 37 ±10 
Gender  




Risk Factors  
Sexual practices  
Heterosexual 90(96) 
MSM 4(15) 
Inconsistent condom use 21(20) 
History of STI  
Ulcerative 12(13) 
Non-ulcerative  15(16)     
Drug use  
Marijuana 1(1) 
Cocaine 0(0) 
IV drug 0(0) 
  
Antiretroviral drug therapy   
Yes 41(44) 
No 53(56) 
*MSM = Men who have sex with men. The cohort of HIV-1 infected patients was predominantly 
heterosexual. 
Table 2. Characteristics of 94 HIV-1 infected patients presenting at the University Hospital of 
the West Indies (UHWI)* 
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Manifestation Frequency (%)  
Constitutional  73(77)  
symptoms  
Skin rashes 46(49)  
  
Opportunistic infection  35(37)  
Respiratory infection  34(36)  
Other STI  21(22) 
Vomiting/diarrhoea 13(14)  
Lymphadenopathy 11(13)   
Neurological  6(6)   
Kaposi sarcoma 1(1)  
Asymptomatic 13(14) 
* Respiratory infections include cough, dyspnea, bacterial pneneumonia, pneumocystis carinii 
pneumonia, otitis media. Opportunistic infections include candidiasis, toxoplasmosis, cytomegalo virus 
infection, scabies, molluscum contagiosum, ulcers, hairy leukoplakia of tongue. Neurological 
manifestations include meningitis and neuralgia. 
Table 3. Clinical manifestations in 94 HIV- infected patients* 
 
CD4 cells/µl 
 Category (N) Mean (± SD) Range 
   
Untreated (32) 378 (341) 5- 1305 
Treated(41) 192 (163) 1- 691 
   
Total (73) 291(140) 1- 1305 
* N = Number of patients in each category. CD4 T Lymphocyte counts were available for 73/94 
patients. The CD4 cells counts were statistically significantly higher in the untreated patients (p< 0.005)  




Age group/years(N) Mean (± SD) Range 
≤ 20 (2) 879 (315) 656 - 1102 
21 - 30 (13) 486 (345) 19 - 1305 
31 - 40 (12) 284 (270) 7 - 684 
41 - 50 (2) 294 (392) 16 - 571 
51 - 60 (3) 8 (2) 5 - 9 
* N = Number of patients in each category. A decreasing trend in CD4 counts with age in untreated 
patients (p<0.05) was observed. 
Table 5. CD4+ T Lymphocyte counts in 32 antiretroviral drug therapy naive patients by age*  
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4.3.2 HIV-1 DNA-PCR assay 
The PCR amplicons obtained included env gene, 141/318 (44.3%), gag gene, 170/318 (53.5%). 
Of the total 318 samples tested, positive results in one or both genes were obtained in 251 
(79%), 113 (113/318, 35.5%) were amplified in both genes while neither the env or gag gene 
was amplified in 67 (21.0%) samples. The results of the HIV-1 env and gag DNA – PCR assays 
are summarized in Table 6. As shown in Figure 3, all gag (35/35,100%) and env (22/22, 
100%) reference subtype plasmids were amplified successfully by all second round primers.  
 
Category Positive(%) Negative(%) 
Env-PCR 141(44.3) 177(55.7) 
Gag-PCR 170(53.5) 148(46.5) 
Env + gag-PCR 113(35.5) 205(64.5) 
Table 6. HIV-1 DNA – PCR assays in 318 HIV- infected patients 
 
Fig. 3. DNA polymerase chain reaction (PCR) assay: Photographs (A-D) of agarose gel 
electrophoresis of PCR products. Lane 1 in each gel contains the base pair (bp) marker. Gels 
A and B show the 748 bp PCR product of the gag gene region of HIV-1 isolates and reference 
strains. Gels C and D show the 1254 bp PCR product of the env gene region of HIV-1 isolates 
and reference strains. 
4.3.3 Heteroduplex mobility assay (HMA) analysis of HIV-1 proviral DNA/isolates 
The env and gag HMA were performed on the PCR amplicons of 180 samples. Of these 174 
(96.7%) were unambiguously genotyped while 6 samples (3.3%) were indeterminate. The 
majority of HIV-1 isolates were subtype B (170/180, 94.4%) while 1 (0.6%) isolate each of 
subtypes A, C, D and E was found. The representative HMA polyacrylamide gel 
photographs in Figures. 4-5 illustrate the endpoint of the HMA procedure and comparative 
electrophoretic mobilities of different HIV subtypes which were found. 
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Fig. 4. Heteroduplex mobility assay (HMA) of HIV-1 strains. Photographs (1-III) of 
polyacrylamide gels showing subtype B strains which formed heteroduplexes with 3 
subtype B reference strains B1 (I), B2 (II) and B3 (III). Heteroduplexes of 11 subtype 
reference strains including A-J strains were tested. The subtypes assigned are those of the 
heteroduplexes with the highest mobility formed between amplicons of the patient’s isolate 
and subtype reference strains. The first lane (m) of each gel contains the Kb marker and the 
last lane (BLK)  the negative control.  
 
Fig. 5. Heteroduplex mobility assay (HMA) of HIV-1 non-B subtype strains. Photographs 
(IV-VII) of polyacrylamide gels showing subtypes A (IV), C (V), D (VI), E (VII). 
Heteroduplexes of 11 subtype reference strains A-J were tested. The subtypes assigned are 
those of the heroduplexes with the highest mobility formed between amplicons of the 
patient’s isolate and reference subtype strains. The first lane (m) of each gel contains the Kb 
marker and the last lane (Blk) the negative control.  
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4.3.4 DNA sequencing and phylogenetic analysis of HIV-1 proviral DNA/isolates 
A total 63 HIV-1 isolates were subjected to automated DNA sequencing which yielded 54 
DNA sequences (54/63, 86%) including 26 gag and 28 env gene region sequences. 
Representative neighbor-joining phylogenetic trees constructed from the gag and env gene 
sequences, respectively are shown in Figures 6-7. Of the 54 sequences 50 (50/54, 93%) were 
assigned subtype B, 2 (2/54, 4%) subtype D and 1 each (1/54, 2%) assigned subtypes A and 
J, respectively. In the gag gene 87% (22/26) clustered with HIV-1 B  subtype reference strains 
(BUS98, BFR, BTH90), 2 (8%) with D subtype reference strain (DUG94), 1 (4%) each with A 
subtype and CRF reference strains (A1 UG92, 18CPXCM) and J subtype reference strain 
(JSE93). The subtype assignments of the gag gene sequences were supported by bootstrap 
values ≥ 70% in 96% (25/26) of isolates. On the other hand all (28/28, 100%) env gene 
sequences clustered with B subtype reference strains (BUS98, BFR, BTH90). The subtype 
assignments of the majority of env gene sequences (25/28) were supported by bootstrap 
values > 90%. The relationships between the Jamaican strains were assessed by the unrooted 
phylogenetic trees constructed from the HIV-1 gag and env sequences. 
 
Fig. 6. Phylogenetic analysis of HIV-1 gag gene sequences of Jamaican isolates: Neighbour-
joining phylogenetic tree constructed from 26 HIV-1 gag sequences, reference subtype 
strains (B US98, B FR, B TH90, D UG94, J SE93, A1 UG92) and circulating recombinant forms 
(18CPXCM). Numbers at the nodes of the tree indicate bootstrap values expressed as the 
percentage of 1000 replicates supporting each subtype in the tree. 
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Fig. 7. Phylogenetic analysis of HIV-1 env gene sequences of Jamaican isolates: Neighbour-
joining phylogenetic tree constructed from 27 Jamaican HIV-1 env sequences and subtype 
reference strains. The Jamaican isolates clustered with subtype B reference strains (BUS98, 
BTH90, BFR83). Supporting bootstrap values, indicated by numbers at internal nodes, are 
expressed as the percentage of 1000 replicates supporting each subtype in the tree.  
4.3.5 Comparison of HIV-1 subtype assignment by HMA and phylogenetic analysis 
For the subtype B viruses which were characterized by both methods there was an overall 
86% (38/44) concordance between phylogenetic analysis and HMA. Of the 6 discordant 
subtype B isolates, 5 were indeterminate and 1 identified as subtype D in the HMA. For non-
B subtypes the rate of concordance was lower (67%, 2/3) as the 2 subtype D viruses were 
identified as subtype E and subtype B, respectively by HMA. The HMA was concordant 
with phylogenetic analysis in discriminating the only subtype A virus in the sample.  
4.3.6 Geographical distribution of HIV-1 subtypes in Jamaica  
The geographical distribution of HIV-1 subtype strains among the parishes in Jamaica is 
shown in Figure 8. Multiple subtypes were found in 3 of the 14 parishes sampled. 
www.intechopen.com
 




Fig. 8. Map of Jamaica showing the geographical distribution of the different HIV-1 subtype 
strains in 14 parishes: Multiple subtypes were found in the parishes of St. Ann (population: 
52,600), Portland (population: 33,000) and the capital city Kingston (population: 157,000).  
4.4 Discussion 
This study of the molecular epidemiology of HIV-1 is the largest and most recent of its kind 
from the English- speaking Caribbean (Cleghorn, 2000; Gittens, 2003; Vaughan, 2003). 
Another important difference between the present study and similar studies conducted in 
the other English-speaking Caribbean countries is the fact that the gag gene of the HIV-1 
isolates was genotyped (Gittens, 2003; Vaughan, 2003). 
The patients whose records were reviewed are representative of the cohort of adult HIV-1 
infected patients from whom peripheral blood mononuclear cells (PBMC) were obtained for 
HIV-1 isolation and molecular typing. The exact time of contracting HIV infection could not 
be ascertained in these patients. However at the time of diagnosis a spectrum of AIDS 
related conditions which defined both primary and late stage HIV-1 infection were seen in 
the  majority of patients whereas a few were asymptomatic (JAMA, 2006). 
The explanation for the late presentation at hospital of some of the patients is beyond the 
scope of this study. What is notable, however, is the relatively long period of time between 
diagnosis and having the required CD4 cell counts done to assess the immune status and 
implement antiretroviral regimens in some patients according to current guidelines (JAMA, 
2006; Office of AIDS Research Advisory Council, 2008). The late presentation, delay in 
immune monitoring and antiretroviral therapy are reflected in the proportion of patients 
whose CD4+ T lymphocyte counts were already below 350 and 200 cells/µl, respectively, at 
the time of testing. This may be due to the fact that CD4 cell determinations and 
antiretroviral drugs only became widely accessible to Jamaican patients under the Global 
HIV/AIDS Programme in mid- 2004.        
The absence of intravenous drug users from the cohort is also worthy of note. Cleghorn et al 
(Cleghorn et al., 2000) also reported an absence of intravenous drug users from a cohort of 
HIV infected patients in Trinidad and Tobago. However other known risk factors for HIV-1 
infection such as history of other STI, inconsistent condom use and multiple sexual partners 
were comparable to that seen in other cohorts including that reported from Trinidad and 
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Tobago and other  Caribbean /West Indian islands (Cleghorn, 2000; Fleming, 1999; Gibney, 
1999; Murphy, 1999). 
In this Jamaican cohort increasing age in antiretroviral drug naïve patients and absence of 
antiretroviral drug therapy in all age categories were the only independent risk factors 
identified for decreasing CD4 T cell counts. This is in keeping with what is known of the 
natural progression of HIV infection (Fox et al., 2008). Although disease progression in HIV-
1 infected patients has been linked with HIV-1 subtypes the impact of different subtypes 
was not assessed in this study as the overwhelming majority of patients were infected with 
subtype B (Baeten , 2007; Kaleebu, 2002; Kanki, 1999). The impact of antiretroviral treatment 
on disease progression was evident as the CD4 T cell counts were significantly lower in the 
group of antiretroviral drug treated patients and similar in the group of patients on 
antiretroviral therapy irrespective of age (Harari, 2004; Hogg, 1999). 
A panel of HIV-1 primer sets from international sources was used in the PCR amplifications. 
Nonetheless failures in amplifications of either gag or env gene were observed in about half 
of the isolates and failures in both genes in about a fifth of isolates. The low sensitivity of the 
HIV PCR assays and the frequent non-concordance between the PCR results for the gag and 
env gene regions might be due to the marked genetic heterogeneity of the virus in both 
genes (Delwart, version 5; Swofford, 2003). This is supported by the fact that all reference 
plasmids were successfully amplified using the primer sets from the National Institutes of 
Health (NIH) prepared kits which failed to amplify a number of the HIV-1 isolates. Other 
authors have encountered the problem of unamplifiable HIV-1 strains with the env primers 
from the HMA kits due to the broad heterogeneity within the gp120 region of the env gene 
(Agwale et al., 2001). For the above mentioned reasons antiretroviral drug use in HIV-
infected patients in Jamaica might not have contributed substantially to genetic variation in 
the env gene as reported by others (Agwale et al., 2001). Six HIV-1 subtypes were identified 
in this study including subtypes A, B, C, D, E and J. It was not entirely surprising to find 
that the majority of HIV-1 isolates in Jamaica were subtype B which accounted for over 90% 
of infections. This is in keeping with reports, from other English speaking Caribbean 
Islands, which did not include Jamaican samples (Gittens, 2003; Vaughan, 2003). Subtype B 
is also the predominant subtype in North America, Western Europe, Australia and South 
America (Distler, 1995; Laukkanen, 2000; Ramos, 1999).  
The percentages of subtypes A, C, D, E and J found in this study were low. However the 
mere presence of these non-B HIV-1 subtypes in the HIV/AIDS population in Jamaica is of 
great importance as it signals high genetic diversity of the virus and the HIV/AIDS 
epidemic. It might be essential that these subtypes be considered in vaccine modeling. 
Outside of Central Africa a limited number of HIV-1 variants are usually circulating in each 
country, rarely more than 2 or 3, representing multiple introductions or in some cases 
locally generated CRFs (Pérez et al., 2006). Subtype A is found in East and Central Africa, 
Central Asia and Eastern Europe with a global prevalence of 12.3% (Hemelaar et al., 2006). 
Subtype C, the dominant subtype in India and China, is the most prevalent subtype 
worldwide accounting for approximately 50% of infections (388, 389). Subtype D is 
generally limited to East and Central Africa with sporadic cases observed in Southern and 
Western Africa (Vogt et al., 1986). Subtype E is a recombinant strain (CRF01_AE), and not a 
distinct subtype as initially thought, which co-circulates with subtype B within the 
intravenous drug user (IDU) population and fishermen in Thailand and also occurs in 
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Vietnam and South East Asia (Entz, 2000; Heyndrickx, 2000; Wasi, 1995). Subtype J occurs in 
various locations with a less than 1% prevalence (Archer, 2007; Hemelaar, 2006). 
The DNA sequencing and phylogenetic analyses performed in the study did not allow 
identification of inter-subtype recombinants as the subtype of the HIV-1 isolates were 
assigned on the DNA sequence of a single gene region, either env or gag (Louwagie, 1993; 
Tatt, 2000). On the other hand genotyping by HMA analysis was performed on the gag and 
env gene sequences of each isolate. This method also failed to identify any recombinant 
strain in Jamaica except for the subtype E strain which was re-assigned subtype D by 
phylogenetic analysis (Heslop  et al., 2005). The subtype A virus identified in this Jamaican 
sample appears to be related, in the gag gene, to CRF18- cpx which originated in Central 
Africa and, currently, is circulating in Cuba (Thomson et al., 2005). It has been reported that 
the genome of CRF18-cpx contains multiple segments clustering with subtypes A1, F, G, H 
and K as well as segments failing to cluster with any subtypes (Thomson et al., 2005). The 
multiple subtypes of HIV-1 in circulation in Jamaica should be monitored for the likely 
emergence of inter-subtype recombinant strains as the epidemic progresses. Recombinant 
strains have been observed mostly in areas where multiple subtypes co-circulate 
(Heyndrickx et al., 2000). The emergence of recombinant strains in other Caribbean and 
Latin American countries, including Cuba and Brazil, following sudden shifts in HIV-1 
subtype distribution from a predominance of subtype B is well documented (Pérez, 2006; 
Santos, 2006; Tatt, 2000; Thomson, 2005).  
The limited divergence of the Jamaican HIV-1 strains, from the subtype reference sequences, 
in the gag and env gene is another important observation. This was evident from the high 
bootstrap values supporting the subtype classification of this sample especially subtype B 
viruses. This might at least be partly explained by the fact that the cohort was largely 
antiretroviral therapy naïve. Secondly the Jamaican HIV-1 isolates which were not amplified 
by the NIH primer sets might include the more divergent strains and these were not 
genotyped (Vaughan et al., 2003). Gittens et al (Gittens et al., 2003) reported a broad genetic 
diversity of env gene sequences in Barbados suggesting multiple introductions of subtype B 
viruses to the island (10). Similarly Cleghorn et al reported a significant subcluster within 
the B subtype in Trinidad (Vaughan et al., 2003).  
The discordance between HMA and phylogenetic analysis in the assignment of subtypes is 
not unique to the present study (Loussert-Ajaka, 1998; Novitski, 1996; Swofford, 2003; 
Thompson, 1994). The HMA has been shown to give excellent results for the detection of 
subtypes B and F, the prevalent subtypes in Caucasian patients originating from Western 
countries and Romania, respectively. Conversely extensive viral variation might create 
problems in countries like Africa where different HIV subtypes have been circulating longer 
(Loussert-Ajaka et al., 1998). This raises the question of whether further problems with the 
HMA might occur in Jamaica with its multiple subtypes of the virus. For example, in 
previous studies of international cohorts, the HIV-1 strains which were deemed un-
typeable/indeterminate by HMA and were subsequently assigned by DNA sequencing 
turned out to be highly divergent subtypes A-D or G related strains (Loussert-Ajaka, 1998; 
Novitski, 1996; Swofford, 2003; Thompson, 1994). In one study almost two thirds of the 
subtype D isolates were incorrectly genotyped by HMA (10). In the present Jamaican sample 
the 2 subtype D viruses were incorrectly genotyped, by HMA, as subtypes B and E, 
respectively (UNAIDS, 2004 - 12). The viruses belonging to subtypes B and D have been 
shown to be closely related with respect to gag, env and pol gene sequences and probably 
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diverged relatively recently. Therefore separation of subtype B and subtype D is not as well 
defined as between other subtypes (Tatt, 2000; UNAIDS/WHO, 2006). Nonetheless the 
HMA remains the recommended genotyping method second only to DNA sequencing. 
Consequently it has been recommended that the plasmid selection in the HMA kit be 
constantly revised to cover viral diversification (Loussert-Ajaka, 1998; Thompson, 1994).  
Limitations of the study include the fact that a substantial proportion of samples were not 
amplifiable by the primer sets which were used. The failure to sequence both the env and 
gag genes of each isolate to indentify inter-subtype recombinants is another limitation. A 
more comprehensive study of the genetic diversity of the Jamaican HIV-1 isolates should 
include customized or more conservative primers, such as those recently described, and 
sequencing pol gene regions (Agwale, 2001; Gittens, 2003; Tatt, 2000). More extensive 
genomic sequence analyses which were not performed in this study might also reveal more 
genetic diversity and linkages among Jamaican isolates. 
4.4.1 Conclusions and recommendations        
Transmission of the multiple subtypes of HIV-1 in the Jamaican population is 
predominantly heterosexual and is not linked to intravenous drug use. HIV-1 subtype B is 
the dominant subtype contributing to the HIV/AIDS epidemic amidst high genetic regions 
of the virus in Jamaica. The results also emphasize the need for genotyping of multiple 
genetic regions, to be attempted, to ensure positive results against the background of 
frequent failures of the necessary PCR assays.  
The HMA is well established as a genotyping method in the Jamaican setting. Our results 
confirm the value of this cost- effective and reliable method in tracking the HIV/AIDS 
epidemic. This does not abrogate the need for DNA sequencing and phylogenetic analysis 
which should be used as an adjunct methodology to resolve indeterminate HMA results and 
ensure the accurate assignment of non-B subtype strains of HIV-1.  
The implications of HIV-1 genetic diversity and its impact on diagnosis, treatment, 
progression and prevention of disease continue to be better understood. Therefore it is 
important that the molecular epidemiology of HIV-1 in Jamaica continue to be monitored 
especially in light of pending vaccines and multiple subtypes of the virus found in Jamaica. 
We recommend the use of the HMA as a major method supported by DNA sequencing and 
phylogenetic analysis for tracking the transmission of the virus. A more comprehensive use 
of DNA sequencing which involves other genetic regions of the virus such as the pol gene 
and more extensive characterization of the genome are required to better elucidate the 
molecular epidemiology of this virus in Jamaica. Further studies also should include 
optimizing the HMA through the development of PCR primers and reference clones of HIV-
1 which are customized for Jamaican strains of HIV-1. 
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